SCHEMBL1343264

SCHEMBL1343264

CC(C)(C)OC(=O)N1CCN(CCCN2CCCC2)C(=O)C1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.42
CHRM2 P08172 2/20 0.40
CHRM1 P11229 2/20 0.40
TLR8 Q9NR97 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38
NR1H2 P55055 1/20 0.38
HPGD P15428 1/20 0.37
ACKR3 P25106 3/20 0.37
KMT5A Q9NQR1 1/20 0.37
MCHR1 Q99705 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
ESR2 Q92731 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM3 P20309 1/20 0.36
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
STAT3 P40763 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1344403 0.92 USP2 (0.41) HRH3CHRM2CHRM1NR1H2HPGD
SCHEMBL2932224 0.89 SMN1; SMN2 (0.49) CHRM2CHRM1TLR8KMT2AUSP2
SCHEMBL1344188 0.88 CHRM2 (0.39) CHRM2CHRM1TLR8HRH2HRH1
SCHEMBL736072 0.88 HPGD (0.41) HRH3CHRM2CHRM1TLR8HPGD
SCHEMBL1343620 0.86 MEN1 (0.39) HRH3CHRM2CHRM1HRH2HRH1
SCHEMBL1583540 0.85 CNR2 (0.40) TLR8NR1H2ESR2USP2SMN1; SMN2
SCHEMBL18205300 0.84 NR1H2 (0.39) CHRM2CHRM1NR1H2MEN1KMT2A
SCHEMBL7982635 0.84 NR1H2 (0.40) CHRM2CHRM1NR1H2MEN1KMT2A
SCHEMBL1341750 0.83 HRH3 (0.37) HRH3CHRM2CHRM1HRH2HRH1
SCHEMBL24072420 0.83 PLA2G2A (0.44) TLR8NR1H2ESR2USP2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063042-B2 Heterocyclic compounds HOFFMANN-LA ROCHE INC. (US) 2011-11-22 US disclosed
EP-2220055-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. Hoffmann-La Roche AG (CH) 2010-08-25 EP disclosed
US-7524852-B2 Bicyclic pyrimidine derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-04-28 US disclosed
US-20090023713-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE, INC. 2009-01-22 US disclosed
WO-2009010429-A2 NOVEL HETEROCYCLYL COMPOUNDS AND THEIR USE AS CHEMOKINE ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-01-22 WO disclosed
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection KYOWA HAKKO KIRIN CO., LTD. (JP) 2007-02-15 US disclosed
EP-1552842-A1 BICYCLIC PYRIMIDINE DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2005-07-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023713-A1 HETEROCYCLIC COMPOUNDS CCR5, CCR3, CCR2 HRH3 137/4885CHRM2 81/4885CHRM1 67/4885
US-20070037834-A1 Anti-inflammatory; cellular infiltration inhibition modulating activity on thymus and activation-regulated chemokine and macrophage-derived chemokine functions; inhibitory activities against binding of TARC and MDC to T cells; allergic disease, autoimmune disease, transplant, graft rejection CX3CR1, CCL5, CCRL2 HRH3 137/4885CHRM2 190/4885CHRM1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.